Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.

Arzneimittel-Forschung - 1 Jan 2009

Petersen Karl-Uwe

Abstract excerpt

Poor or lacking responses to the antiplatelet effect of clopidogrel (CAS 113665-84-2) and the attendant clinical consequences have been a growing concern for several years. This debate has been invigorated by reports suggesting the ability of inhibitors of the cytochrome P450 isoenzyme, CYP 2C19, to interfere with clopidogrel efficacy. In the present review, the mechanisms underlying clopidogrel failure are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Clopidogrel
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Platelet Aggregation Inhibitors

Share to Prasugrel Hydrochloride

Share to Thiophenes

Share to Ticlopidine

Source

Identifiers

PMID: 19537521
DOI: 10.1055/s-0031-1296388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.PMID 19537521Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

CYP-mediated pharmacologic interference with optimal platelet inhibition.Semantic proximity Read ↗

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.Semantic proximity Read ↗

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.Semantic proximity Read ↗

A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of ClopidogrelSemantic proximity Read ↗

[Clopidogrel resistance--risk factor in patients with acute coronary syndromes].Semantic proximity Read ↗

The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.Semantic proximity Read ↗

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.Semantic proximity Read ↗

Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Semantic proximity Read ↗

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Semantic proximity Read ↗

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.Semantic proximity Read ↗

The clopidogrel conundrum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.